期刊
SCIENCE
卷 342, 期 6161, 页码 979-983出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1245321
关键词
-
资金
- NIH [5R01GM069530, GM58160]
- National Research Service Award (NRSA) fellowship [F32NS061419, F32GM099817]
- JPB Foundation
- Eleanor Schwartz Charitable Foundation
- HHMI
- Bachmann-Strauss Dystonia & Parkinson Foundation
alpha-Synuclein (alpha-syn) is a small lipid-binding protein implicated in several neurodegenerative diseases, including Parkinson's disease, whose pathobiology is conserved from yeast to man. There are no therapies targeting these underlying cellular pathologies, or indeed those of any major neurodegenerative disease. Using unbiased phenotypic screens as an alternative to target-based approaches, we discovered an N-aryl benzimidazole (NAB) that strongly and selectively protected diverse cell types from alpha-syn toxicity. Three chemical genetic screens in wild-type yeast cells established that NAB promoted endosomal transport events dependent on the E3 ubiquitin ligase Rsp5/Nedd4. These same steps were perturbed by alpha-syn itself. Thus, NAB identifies a druggable node in the biology of alpha-syn that can correct multiple aspects of its underlying pathology, including dysfunctional endosomal and endoplasmic reticulum-to-Golgi vesicle trafficking.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据